跳至主要内容
临床试验/NCT01078285
NCT01078285已完成不适用

Impact Of An Integrated Intervention Program On Adherence To Atorvastatin

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.3 个研究点 分布在 1 个国家目标入组 500 人开始时间: 2010年3月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
500
试验地点
3
主要终点
Proportion of Days Covered (PDC)

研究概览

简要总结

Despite extensive reports of the benefits of statins in reducing serious cardiovascular events such as stroke and heart disease in patients with elevated LDL-cholesterol, patients do not take their medicines regularly as prescribed. Reasons include forgetfulness, lack of understanding of the seriousness of the disease, and fear of side effects. An intervention strategy comprising 3-5 minutes of counseling, emotional support and cost-sharing may be motivational and improve adherence to treatment.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
21 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female aged >21 years
  • Have received a new or re-fil prescription for atorvastatin at first study visit to Prairie Heart Institute
  • Signed informed consent

排除标准

  • Unwilling to give written informed consent
  • Failed statin treatment in the past
  • Switched from another statin to atorvastatin because of co-pay program
  • Participated in an earlier Market Research study on Impact of cholesterol management behaviors post in-clinic adherence intervention

结局指标

主要结局

Proportion of Days Covered (PDC)

时间窗: 180 days

次要结局

  • Medication Possession Ratio (MPR)(180 days)
  • Percent of patients who fill at least one atorvastatin prescription during the period of study(180 days)
  • Persistence-the number of continuous days a patient is supplied with medication using the allowable grace period or gap (30 or 60 days).(180 days)
  • Percent of patients that are at least 80% adherent (PDC>0.8)(180 days)

研究者

发起方
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (3)

Loading locations...

相似试验